Madhura R. Pandkar

Madhura R. Pandkar

Auto-generated profile, based on publicly available information

Madhura R. Pandkar

Department of Medicine, Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Translational Oncology
Verified
Journal Article
Open access
MPMadhura R. Pandkar
Madhura R. Pandkar
SSSommya Sinha
Sommya Sinha
ASAtul Samaiya
Atul Samaiya
SSSanjeev Shukla
Sanjeev Shukla
Due to the enhanced glycolytic rate, cancer cells generate lactate copiously, subsequently promoting the lactylation of histones. While previous studies have explored the impact of histone lactylation in modulating gene expression, the precise role of this epigenetic modification in regulating oncogenes is largely unchartered. In this study, using breast cancer cell lines and their mutants exhibiting lactate-deficient metabolome, we have identified that an enhanced rate of aerobic glycolysis supports c-Myc expression via promoter-level histone lactylation. Interestingly, c-Myc further transcriptionally upregulates serine/arginine splicing factor 10 (SRSF10) to drive alternative splicing of MDM4 and Bcl-x in breast cancer cells. Moreover, our results reveal that restricting the activity of critical glycolytic enzymes affects the c-Myc-SRSF10 axis to subside the proliferation of breast cancer cells. Our findings provide novel insights into the mechanisms by which aerobic glycolysis influences alternative splicing processes that collectively contribute to breast tumorigenesis. Furthermore, we also envisage that chemotherapeutic interventions attenuating glycolytic rate can restrict breast cancer progression by impeding the c-Myc-SRSF10 axis.

9 June 2023 in NAR Cancer
Verified
Journal Article
Open access
PDF file
MPMadhura R Pandkar
Madhura R Pandkar
ARAdarsh Raveendran
Adarsh Raveendran
KBKajal Biswas
Kajal Biswas
SMSrinivas Abhishek Mutnuru
Srinivas Abhishek Mutnuru
JMJharna Mishra
Jharna Mishra
SSSanjeev Shukla
Sanjeev Shukla
The hypoxic milieu is a critical modulator of aerobic glycolysis, yet the regulatory mechanisms between the key glycolytic enzymes in hypoxic cancer cells are largely unchartered. In particular, the M2 isoform of pyruvate kinase (PKM2), the rate-limiting enzyme of glycolysis, is known to confer adaptive advantages under hypoxia. Herein, we report that non-canonical PKM2 mediates HIF-1α and p300 enrichment at PFKFB3 hypoxia-responsive elements (HREs), causing its upregulation. Consequently, the absence of PKM2 activates an opportunistic occupancy of HIF-2α, along with acquisition of a poised state by PFKFB3 HREs-associated chromatin. This poised nature restricts HIF-2α from inducing PFKFB3 while permitting the maintenance of its basal-level expression by harboring multiple histone modifications. In addition, the clinical relevance of the study has been investigated by demonstrating that Shikonin blocks the nuclear translocation of PKM2 to suppress PFKFB3 expression. Furthermore, TNBC patient-derived organoids and MCF7 cells-derived xenograft tumors in mice exhibited substantial growth inhibition upon shikonin treatment, highlighting the vitality of targeting PKM2. Conclusively, this work provides novel insights into the contributions of PKM2 in modulating hypoxic transcriptome and a previously unreported poised epigenetic strategy exhibited by the hypoxic breast cancer cells for ensuring the maintenance of PFKFB3 expression.

30 May 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SLSophia M. Lamperis
Sophia M. Lamperis
KMKaylin M. McMahon
Kaylin M. McMahon
ACAndrea E. Calvert
Andrea E. Calvert
JRJonathan S. Rink
Jonathan S. Rink
KVKarthik Vasan
Karthik Vasan
CTC. Shad Thaxton
C. Shad Thaxton
Ferroptosis is a cell death mechanism distinguished by its dependence on iron-mediated lipid oxidation. Cancer cells highly resistant to conventional therapies often demonstrate lipid metabolic and redox vulnerabilities that sensitize them to cell death by ferroptosis. These include a unique dependency on the lipid antioxidant selenoenzyme, glutathione peroxidase 4 (GPx4), that acts as a ferroptosis inhibitor. Synthetic high-density lipoprotein-like nanoparticle (HDL NP) targets the high-affinity HDL receptor scavenger receptor class B type 1 (SR-B1) and regulates cell and cell membrane lipid metabolism. Recently, we reported that targeting cancer cell SR-B1 with HDL NP depleted cell GPx4, which is accompanied by increased cell membrane lipid peroxidation and cancer cell death. These data suggest that HDL NP may induce ferroptosis. Thus, we conducted an unbiased CRISPR-based positive selection screen and target validation studies in ovarian clear cell carcinoma (OCCC) cell lines to ascertain the mechanism through which HDL NP regulates GPx4 and kills cancer cells. The screen revealed two genes, acyl-CoA synthetase long chain family member 4 (ACSL4) and thioredoxin reductase 1 (TXNRD1), whose loss conferred resistance to HDL NP. Validation of ACSL4 supports that HDL NP induces ferroptosis as the predominant mechanism of cell death, while validation of TXNRD1 revealed that HDL NP reduces cellular selenium and selenoprotein production, most notably, GPx4. Accordingly, we define cancer cell metabolic targets that can be simultaneously actuated by a multifunctional, synthetic HDL NP ligand of SR-B1 to kill cancer cells by ferroptosis.

15 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MPMadhura R. Pandkar
Madhura R. Pandkar
SSSommya Sinha
Sommya Sinha
ASAtul Samaiya
Atul Samaiya
SSSanjeev Shukla
Sanjeev Shukla
Owing to the enhanced glycolytic rate, cancer cells generate lactate copiously, which in turn, promotes lactylation of histone. Even though histone lactylation has been explored to alter the expression of few genes, the role of this epigenetic modification in regulating the expression of oncogenes is largely unchartered. In this study, using breast cancer cell lines their mutants (which exhibit lactate-deficient metabolome), we have identified that intracellular lactate promotes histone lactylation-dependent c-Myc upregulation. Furthermore, we report that the c-Myc upregulates serine/arginine splicing factor 10 ( SRSF10 ) to drive alternative splicing in breast cancer cells. Our findings provide novel mechanistic insights into the role assayed by aerobic glycolysis in orchestrating alternative splicing that collectively drive breast tumorigenesis. Moreover, we also envisage that chemotherapeutic interventions attenuating glycolytic rate can restrict breast cancer progression by impeding the c-Myc-SRSF10 axis.

7 November 2026 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
ADAyden Matthew Dant
Ayden Matthew Dant
BNBehnaz Namdarzadeh
Behnaz Namdarzadeh
MPMadhura R. Pandkar
Madhura R. Pandkar
AGAlvaro Rodriguez Gonzalez
Alvaro Rodriguez Gonzalez
SSSuresh Subedi
Suresh Subedi
KKKeerthi Krishnan
Keerthi Krishnan